CN105073715B - 二氢哒嗪‑3,5‑二酮衍生物 - Google Patents

二氢哒嗪‑3,5‑二酮衍生物 Download PDF

Info

Publication number
CN105073715B
CN105073715B CN201480013485.6A CN201480013485A CN105073715B CN 105073715 B CN105073715 B CN 105073715B CN 201480013485 A CN201480013485 A CN 201480013485A CN 105073715 B CN105073715 B CN 105073715B
Authority
CN
China
Prior art keywords
methyl
group
substituted
alkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480013485.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105073715A (zh
Inventor
大竹义仁
冈本直树
小野芳幸
柏木浩孝
金原笃
原田武雄
堀伸行
村田佳久
橘生
橘一生
田中翔太
野村研
野村研一
井出光昭
水口荣作
市田康弘
大友秀
大友秀一
堀场直
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN105073715A publication Critical patent/CN105073715A/zh
Application granted granted Critical
Publication of CN105073715B publication Critical patent/CN105073715B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Luminescent Compositions (AREA)
CN201480013485.6A 2013-03-13 2014-03-13 二氢哒嗪‑3,5‑二酮衍生物 Active CN105073715B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2013051082 2013-03-13
JP2013-051082 2013-03-13
JP2013-132889 2013-06-25
JP2013132889 2013-06-25
PCT/JP2014/056778 WO2014142273A1 (ja) 2013-03-13 2014-03-13 ジヒドロピリダジン－３，５－ジオン誘導体

Publications (2)

Publication Number Publication Date
CN105073715A CN105073715A (zh) 2015-11-18
CN105073715B true CN105073715B (zh) 2017-12-01

Family

ID=51536921

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480013485.6A Active CN105073715B (zh) 2013-03-13 2014-03-13 二氢哒嗪‑3,5‑二酮衍生物

Country Status (29)

Country Link
EP (2) EP3757093A1 (OSRAM)
JP (2) JP5814488B2 (OSRAM)
KR (2) KR101664460B1 (OSRAM)
CN (1) CN105073715B (OSRAM)
AU (1) AU2014230552B2 (OSRAM)
BR (1) BR112015022092B1 (OSRAM)
CA (1) CA2901868C (OSRAM)
CL (1) CL2015002543A1 (OSRAM)
CR (1) CR20150505A (OSRAM)
DK (1) DK2975030T3 (OSRAM)
ES (1) ES2811126T3 (OSRAM)
HR (1) HRP20201211T1 (OSRAM)
HU (1) HUE050577T2 (OSRAM)
IL (1) IL240825B (OSRAM)
LT (1) LT2975030T (OSRAM)
MX (1) MX376532B (OSRAM)
MY (1) MY174269A (OSRAM)
NZ (1) NZ711182A (OSRAM)
PE (1) PE20151535A1 (OSRAM)
PH (1) PH12015501940A1 (OSRAM)
PL (1) PL2975030T3 (OSRAM)
PT (1) PT2975030T (OSRAM)
RS (1) RS60911B1 (OSRAM)
RU (1) RU2662832C2 (OSRAM)
SG (1) SG11201507345RA (OSRAM)
SI (1) SI2975030T1 (OSRAM)
TW (2) TWI596095B (OSRAM)
UA (1) UA118755C2 (OSRAM)
WO (1) WO2014142273A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20201211T1 (hr) * 2013-03-13 2020-11-13 Chugai Seiyaku Kabushiki Kaisha Derivat dihidropiridazin-3,5-diona
EP3928779B1 (en) * 2014-09-12 2024-03-06 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical containing sodium-dependent phosphate transporter inhibitor and phosphorus adsorbent for use in the prevention, treatment or suppression of chronic kidney disease, arteriosclerosis associated with vascular calcification, or ectopic calcification.
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CN110885290A (zh) * 2019-12-16 2020-03-17 阿里生物新材料（常州）有限公司 一种3-氟-2-甲基-4-三氟甲基苯胺盐酸盐的合成方法
CN115734965B (zh) 2020-06-26 2025-05-02 日本农药株式会社 芳基四氢哒嗪衍生物或其盐类、和含有该化合物的杀虫剂及其使用方法
WO2022221182A1 (en) * 2021-04-12 2022-10-20 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc34a1 function
KR20240018523A (ko) 2021-06-08 2024-02-13 추가이 세이야쿠 가부시키가이샤 다이하이드로피리다진-3,5-다이온 유도체를 함유하는 제제
AR126060A1 (es) * 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd Método para producir derivado de dihidropiridazin-3,5-diona
WO2023127805A1 (ja) 2021-12-28 2023-07-06 日本農薬株式会社 アリールテトラヒドロピリダジン誘導体又はその塩類及び該化合物を含有する殺虫剤並びにその使用方法
WO2023219127A1 (ja) 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物
CN116217862A (zh) * 2023-03-21 2023-06-06 中国农业科学院农业环境与可持续发展研究所 一种可降解生物膜助剂的制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070707A1 (en) * 2002-02-19 2003-08-28 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
CN1662529A (zh) * 2002-06-19 2005-08-31 默克专利有限公司 作为磷酸二酯酶iv抑制剂的噻唑衍生物
CN101501006A (zh) * 2006-05-31 2009-08-05 P.安杰莱蒂分子生物学研究所 作为聚(adp-核糖)聚合酶(parp)抑制剂的吡啶酮和哒嗪酮衍生物
CN101626767A (zh) * 2005-05-18 2010-01-13 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
CN102264740A (zh) * 2008-08-20 2011-11-30 菲布罗根有限公司 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
WO2012006474A2 (en) * 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
CN102869656A (zh) * 2010-04-28 2013-01-09 安斯泰来制药株式会社 四氢苯并噻吩化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017900B1 (ru) * 2006-11-03 2013-04-30 Басф Се Способ получения дифторметилпиразолилкарбоксилатов
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2012006475A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
PL2772490T3 (pl) 2011-10-27 2016-11-30 Aminoalkilo-podstawiona pochodna n-tienylobenzamidu
HRP20201211T1 (hr) * 2013-03-13 2020-11-13 Chugai Seiyaku Kabushiki Kaisha Derivat dihidropiridazin-3,5-diona

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070707A1 (en) * 2002-02-19 2003-08-28 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
CN1662529A (zh) * 2002-06-19 2005-08-31 默克专利有限公司 作为磷酸二酯酶iv抑制剂的噻唑衍生物
CN101626767A (zh) * 2005-05-18 2010-01-13 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
CN101501006A (zh) * 2006-05-31 2009-08-05 P.安杰莱蒂分子生物学研究所 作为聚(adp-核糖)聚合酶(parp)抑制剂的吡啶酮和哒嗪酮衍生物
CN102264740A (zh) * 2008-08-20 2011-11-30 菲布罗根有限公司 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
CN102869656A (zh) * 2010-04-28 2013-01-09 安斯泰来制药株式会社 四氢苯并噻吩化合物
WO2012006474A2 (en) * 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
慢性肾衰竭高磷血症研究及治疗进展;苗华，等;《中国血液净化》;20070912;第6卷(第9期);第500-502页 *

Also Published As

Publication number Publication date
JP2016040262A (ja) 2016-03-24
EP2975030A1 (en) 2016-01-20
PL2975030T3 (pl) 2021-01-11
PH12015501940B1 (en) 2016-01-11
KR20160119282A (ko) 2016-10-12
PH12015501940A1 (en) 2016-01-11
EP2975030B1 (en) 2020-07-15
JP6420738B2 (ja) 2018-11-07
AU2014230552A1 (en) 2015-08-13
BR112015022092A8 (pt) 2018-01-23
IL240825B (en) 2020-07-30
CR20150505A (es) 2015-10-26
MY174269A (en) 2020-04-01
JP5814488B2 (ja) 2015-11-17
RU2662832C2 (ru) 2018-07-31
MX376532B (es) 2025-03-07
BR112015022092B1 (pt) 2023-04-11
TWI596095B (zh) 2017-08-21
RU2015143507A (ru) 2017-04-19
ES2811126T3 (es) 2021-03-10
EP3757093A1 (en) 2020-12-30
MX2015012537A (es) 2016-02-10
HK1212700A1 (zh) 2016-06-17
KR101664460B1 (ko) 2016-10-10
CA2901868C (en) 2022-05-03
TWI683811B (zh) 2020-02-01
UA118755C2 (uk) 2019-03-11
KR20150127721A (ko) 2015-11-17
WO2014142273A1 (ja) 2014-09-18
PE20151535A1 (es) 2015-10-28
DK2975030T3 (da) 2020-08-31
IL240825A0 (en) 2015-10-29
CL2015002543A1 (es) 2016-02-26
CN105073715A (zh) 2015-11-18
RS60911B1 (sr) 2020-11-30
TW201741304A (zh) 2017-12-01
HUE050577T2 (hu) 2020-12-28
SG11201507345RA (en) 2015-10-29
LT2975030T (lt) 2020-09-25
HRP20201211T1 (hr) 2020-11-13
KR102072268B1 (ko) 2020-01-31
AU2014230552B2 (en) 2017-11-16
BR112015022092A2 (pt) 2017-07-18
TW201446756A (zh) 2014-12-16
PT2975030T (pt) 2020-09-28
EP2975030A4 (en) 2016-08-03
JPWO2014142273A1 (ja) 2017-02-16
SI2975030T1 (sl) 2020-10-30
CA2901868A1 (en) 2014-09-18
NZ711182A (en) 2020-05-29

Similar Documents

Publication Publication Date Title
CN105073715B (zh) 二氢哒嗪‑3,5‑二酮衍生物
CN113272303B (zh) 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN107072993B (zh) 含有钠依赖性磷酸转运蛋白抑制剂的药物
WO2024083256A1 (zh) pan-KRAS降解剂及其制备方法和应用
WO2018166493A1 (zh) 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
WO2023109883A1 (zh) 一类芳杂环取代的化合物及其制备方法和用途
CN110461842A (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
CN108779115B (zh) 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用
HK1235279B (zh) 含有钠依赖性磷酸转运蛋白抑制剂的药物
HK1212700B (en) Dihydropyridazine-3,5-dione derivative
HK1235279A1 (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
WO2025161532A1 (zh) Pde4b抑制剂及其药物组合物和用途
RU2811864C1 (ru) Фармацевтическое средство, содержащее ингибитор натрийзависимого переносчика фосфата
CN119613397A (zh) N杂芳并环-3-磺酰胺类化合物及其用于制备gpr17受体抑制剂中的用途
WO2024061366A1 (zh) 具有磷酰化芳基结构的小分子化合物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1212700

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1212700

Country of ref document: HK